183 related articles for article (PubMed ID: 36211342)
21. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
Kim H; Sanchez GA; Goldbach-Mansky R
J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
[TBL] [Abstract][Full Text] [Related]
22. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
[TBL] [Abstract][Full Text] [Related]
23. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
Gallucci S; Meka S; Gamero AM
Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
[TBL] [Abstract][Full Text] [Related]
24. Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies.
Lodi L; Melki I; Bondet V; Seabra L; Rice GI; Carter E; Lepelley A; Martin-Niclós MJ; Al Adba B; Bader-Meunier B; Barth M; Blauwblomme T; Bodemer C; Boespflug-Tanguy O; Dale RC; Desguerre I; Ducrocq C; Dulieu F; Dumaine C; Ellul P; Hadchouel A; Hentgen V; Hié M; Hully M; Jeziorski E; Lévy R; Mochel F; Orcesi S; Passemard S; Pouletty M; Quartier P; Renaldo F; Seidl R; Shetty J; Neven B; Blanche S; Duffy D; Crow YJ; Frémond ML
J Clin Immunol; 2021 Apr; 41(3):603-609. PubMed ID: 33411153
[TBL] [Abstract][Full Text] [Related]
25. Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.
Gairhe S; Awad KS; Dougherty EJ; Ferreyra GA; Wang S; Yu ZX; Takeda K; Demirkale CY; Torabi-Parizi P; Austin ED; Elinoff JM; Danner RL
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836561
[TBL] [Abstract][Full Text] [Related]
26. The role of interferons type I, II and III in myositis: A review.
Bolko L; Jiang W; Tawara N; Landon-Cardinal O; Anquetil C; Benveniste O; Allenbach Y
Brain Pathol; 2021 May; 31(3):e12955. PubMed ID: 34043262
[TBL] [Abstract][Full Text] [Related]
27. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
[TBL] [Abstract][Full Text] [Related]
28. Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20.
Schwartz DM; Blackstone SA; Sampaio-Moura N; Rosenzweig S; Burma AM; Stone D; Hoffmann P; Jones A; Romeo T; Barron KS; Waldman MA; Aksentijevich I; Kastner DL; Milner JD; Ombrello AK
Ann Rheum Dis; 2020 Mar; 79(3):429-431. PubMed ID: 31767699
[No Abstract] [Full Text] [Related]
29. Type I Interferonopathies in Childhood.
Haşlak F; Kılıç Könte E; Aslan E; Şahin S; Kasapçopur Ö
Balkan Med J; 2023 May; 40(3):165-174. PubMed ID: 37161741
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell transplantation in a patient with proteasome-associated autoinflammatory syndrome (PRAAS).
Verhoeven D; Schonenberg-Meinema D; Ebstein F; Papendorf JJ; Baars PA; van Leeuwen EMM; Jansen MH; Lankester AC; van der Burg M; Florquin S; Maas SM; van Koningsbruggen S; Krüger E; van den Berg JM; Kuijpers TW
J Allergy Clin Immunol; 2022 Mar; 149(3):1120-1127.e8. PubMed ID: 34416217
[TBL] [Abstract][Full Text] [Related]
31. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.
Maria NI; Brkic Z; Waris M; van Helden-Meeuwsen CG; Heezen K; van de Merwe JP; van Daele PL; Dalm VA; Drexhage HA; Versnel MA
Ann Rheum Dis; 2014 Jun; 73(6):1052-9. PubMed ID: 23831963
[TBL] [Abstract][Full Text] [Related]
32. Type I IFN-related NETosis in ataxia telangiectasia and Artemis deficiency.
Gul E; Sayar EH; Gungor B; Eroglu FK; Surucu N; Keles S; Guner SN; Findik S; Alpdundar E; Ayanoglu IC; Kayaoglu B; Geckin BN; Sanli HA; Kahraman T; Yakicier C; Muftuoglu M; Oguz B; Cagdas Ayvaz DN; Gursel I; Ozen S; Reisli I; Gursel M
J Allergy Clin Immunol; 2018 Jul; 142(1):246-257. PubMed ID: 29155101
[TBL] [Abstract][Full Text] [Related]
33. Development of a Validated Interferon Score Using NanoString Technology.
Kim H; de Jesus AA; Brooks SR; Liu Y; Huang Y; VanTries R; Montealegre Sanchez GA; Rotman Y; Gadina M; Goldbach-Mansky R
J Interferon Cytokine Res; 2018 Apr; 38(4):171-185. PubMed ID: 29638206
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.
Rice GI; Melki I; Frémond ML; Briggs TA; Rodero MP; Kitabayashi N; Oojageer A; Bader-Meunier B; Belot A; Bodemer C; Quartier P; Crow YJ
J Clin Immunol; 2017 Feb; 37(2):123-132. PubMed ID: 27943079
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.
Volpi S; Insalaco A; Caorsi R; Santori E; Messia V; Sacco O; Terheggen-Lagro S; Cardinale F; Scarselli A; Pastorino C; Moneta G; Cangemi G; Passarelli C; Ricci M; Girosi D; Derchi M; Bocca P; Diociaiuti A; El Hachem M; Cancrini C; Tomà P; Granata C; Ravelli A; Candotti F; Picco P; DeBenedetti F; Gattorno M
J Clin Immunol; 2019 Jul; 39(5):476-485. PubMed ID: 31144250
[TBL] [Abstract][Full Text] [Related]
36. Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia.
Ugolini-Lopes MR; Torrezan GT; Gândara APR; Olivieri EHR; Nascimento IS; Okazaki E; Bonfá E; Carraro DM; de Andrade DCO
Autoimmun Rev; 2019 Apr; 18(4):393-398. PubMed ID: 30772492
[TBL] [Abstract][Full Text] [Related]
37. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
Jiang J; Zhao M; Chang C; Wu H; Lu Q
Clin Rev Allergy Immunol; 2020 Oct; 59(2):248-272. PubMed ID: 32557263
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
[TBL] [Abstract][Full Text] [Related]
39. Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus.
Tesser A; de Carvalho LM; Sandrin-Garcia P; Pin A; Pastore S; Taddio A; Roberti LR; de Paula Queiroz RG; Ferriani VPL; Crovella S; Tommasini A
Arthritis Res Ther; 2020 Apr; 22(1):91. PubMed ID: 32334613
[TBL] [Abstract][Full Text] [Related]
40. Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.
Melki I; Frémond ML
Curr Rheumatol Rep; 2020 Jun; 22(7):32. PubMed ID: 32548765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
